Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

17.63 -1.14 (-6.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Why Travere Therapeutics Stock Bolted Higher This Week
A high-value regulatory approval lit a fire underneath the biotech's shares this week. 
Via The Motley Fool
Travere Therapeutics's Earnings Outlook
 
Via Benzinga
What 10 Analyst Ratings Have To Say About Travere Therapeutics
 
Via Benzinga
The Latest Analyst Ratings for Travere Therapeutics
 
Via Benzinga
4 Analysts Have This to Say About Travere Therapeutics
 
Via Benzinga
Where Travere Therapeutics Stands With Analysts
 
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
 
Via Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
These two growth stocks might deliver enormous gains for shareholders this month. 
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2023 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  Monday saw 196 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 160 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS